Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.

ABSTRACT: BACKGROUND:Immune checkpoint inhibitor (ICI)-induced pancreatic injury (ICIPI) is not well documented in the literature. We aimed to describe the clinical characteristics and outcomes of patients who developed ICIPI. METHODS:We reviewed the medical records of consecutive patients who had a confirmed diagnosis of ICIPI (Common Terminology Criteria for Adverse Events grade???3 lipase elevation with or without clinical symptoms) from April 2011 through April 2018. RESULTS:Among the 2,279 patients received ICI and had lipase values checked thereafter, 82 (4%) developed ICIPI. Overall, 65% of patients received inhibitors of programmed death protein-1 or its ligand. Compared with asymptomatic presentation, patients who had clinical symptoms of pancreatitis (n?=?32) had higher levels of lipase (P?=?0.032), more frequent imaging evidence of pancreatitis (P?=?0.055), and more frequent hospitalization (P?

SUBMITTER: Abu-Sbeih H 

PROVIDER: S-EPMC6364483 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature